Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer
Authors
Keywords
mTOR, Pancreatic cancer, Capecitabine, Phase II, Targeted therapy, Everolimus
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 75, Issue 6, Pages 1135-1141
Publisher
Springer Nature
Online
2015-03-30
DOI
10.1007/s00280-015-2730-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer
- (2014) Mareile Joka et al. ANTI-CANCER DRUGS
- Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients
- (2013) Su Jin Lee et al. INVESTIGATIONAL NEW DRUGS
- Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies
- (2011) Maarten J. Deenen et al. INVESTIGATIONAL NEW DRUGS
- A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
- (2011) György Bodoky et al. INVESTIGATIONAL NEW DRUGS
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab and everolimus in the treatment of patients with metastatic melanoma
- (2010) John D. Hainsworth et al. CANCER
- Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells
- (2010) Xinxin Bu et al. CANCER BIOLOGY & THERAPY
- Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab
- (2010) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors
- (2009) J.-C. Soria et al. ANNALS OF ONCOLOGY
- Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
- (2009) M Campone et al. BRITISH JOURNAL OF CANCER
- A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
- (2009) Robert J. Amato et al. CANCER
- Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer
- (2009) Taro Matsuzaki et al. CANCER SCIENCE
- Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors
- (2009) I. Okamoto et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
- (2009) Susan L. Ellard et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
- (2008) J LOPICCOLO et al. DRUG RESISTANCE UPDATES
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- (2008) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
- (2008) Anne O'Donnell et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
- (2008) Brian M. Wolpin et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started